The widely known blood-thinning drug, Plavix - or clopidogrel - is the target of lawsuits filed by thousands of patients who claim that the drug, meant to reduce the risk of blood clots in those with higher risk of cardiovascular problems, instead caused detrimental health issues. The problems range from ineffective therapeutic treatment, to severe bleeding, and has even resulted in the death of almost 20 patients. Those filing suite claim negligence, false or misleading advertising, and wrongful death, according to the article featured below.
"In 2009, the FDA published an advisory saying Plavix may have reduced effectiveness in patients who don’t metabolize the drug well.
In 2010, the FDA issued a “black box” warning for Plavix on its reduced effectiveness for certain patients." (Mills, Huffington Post)
A similarly-based lawsuit in Hawaii of Bristol-Meyers Squibb and Sanofi - the manufacturers of Plavix - was brought forth saying that the companies failed to disclose that 30 percent of the population concerned would not benefit from Plavix based on their genetics, heightening the risk for gastrointestinal bleeding.
Both a greater understanding of one's health history via personalized medicine approaches and the responsible communication of governing and administering pharmaceutical bodies are needed in the hopes of reaching higher levels of personal precision healthcare.
Continue to the article below for more on this case.